Scientists break through pancreas cancer treatment barrier
Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor ...
Cancer
Mar 19, 2012 |
5 / 5 (2) |
0
|
Paragazole excels in preclinical models of triple-negative breast cancer
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative ...
Cancer
Apr 08, 2013 |
5 / 5 (2) |
0
Combination therapy may enhance gemcitabine activity
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Di ...
Cancer
Feb 28, 2012 |
3 / 5 (2) |
0
New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd ...
Cancer
Apr 18, 2012 |
5 / 5 (1) |
0
Study shows drug combination extends pancreatic cancer patient survival
A multi-center Phase III clinical trial demonstrates that Abraxane (nab-paclitaxel) plus gemcitabine is the first combination of cancer drugs to extend survival of late-stage pancreatic cancer patients compared to standard ...
Cancer
Jan 22, 2013 |
5 / 5 (1) |
0
Two-drug combo more effective in treating sarcomas, study shows
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors. They report ...
Cancer
Apr 09, 2013 |
5 / 5 (1) |
0
|
